Search Results - "Hiramatsu, Hidetaka"

Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal‐onset seizures with newly diagnosed or currently untreated recurrent epilepsy: A post hoc analysis of the open‐label Study 342 (FREEDOM) by Husni, Ryan Edbert, Ngo, Leock Y., Senokuchi, Hirofumi, Patten, Anna, Hiramatsu, Hidetaka, Watanabe, Kazuaki, Yamamoto, Takamichi

“…Objective This post hoc analysis evaluated whether continued treatment with perampanel monotherapy beyond initial titration may be appropriate for patients…”
Get full text

Efficacy and safety of perampanel monotherapy in patients with focal‐onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open‐label Study 342 (FREEDOM Study) by Yamamoto, Takamichi, Lim, Sung Chul, Ninomiya, Hirotomo, Kubota, Yuichi, Shin, Won Chul, Kim, Dong Wook, Shin, Dong Jin, Hoshida, Tohru, Iida, Koji, Ochiai, Taku, Matsunaga, Risa, Higashiyama, Hiroyuki, Hiramatsu, Hidetaka, Kim, Ji Hyun

“…Objective Our study assessed perampanel monotherapy in patients (aged ≥12 years) with focal‐onset seizures (FOS) with or without focal to bilateral…”
Get full text

Perampanel Monotherapy Beyond Initial Titration to Achieve Seizure Freedom in Patients With Partial-Onset Seizures (POS), With/Without Secondarily Generalized Seizures (SGS): Post Hoc Analysis of Phase III Study 342 (FREEDOM) (1969) by Husni, Ryan Edbert, Ngo, Leock Y., Patten, Anna, Hiramatsu, Hidetaka, Watanabe, Kazuaki, Senokuchi, Hirofumi, Yamamoto, Takamichi

“…Abstract only…”
Get full text

Efficacy and Safety of Perampanel Monotherapy in Patients with Newly Diagnosed or Currently Untreated Recurrent Partial-Onset Seizures (POS): Final Analysis of Study 342 (FREEDOM) 4 and 8 mg/day Core Data (833) by Yamamoto, Takamichi, Kim, Ji Hyun, Lim, Sung Chul, Ninomiya, Hirotomo, Kubota, Yuichi, Matsunaga, Risa, Hiramatsu, Hidetaka

“…Abstract only…”
Get full text

Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy by Usui, Naotaka, Akamatsu, Naoki, Nakasato, Nobukazu, Ohnishi, Akihiro, Kaneko, Sunao, Hiramatsu, Hidetaka, Saeki, Kazunori, Miyagishi, Hideaki, Inoue, Yushi

“…•Studies 231/233 assessed perampanel tolerability in Japanese patients with POS.•33.3% of patients completing Study 231 achieved a maximum tolerated dose of 12…”
Get full text